Trump's psychedelics executive order: what it does, what came before, and the science behind it
By Shawn Geddes
On the morning of April 18, 2026, President Donald Trump signed an executive order titled "Accelerating Medical Treatments for Serious Mental Illness," directing federal agencies to fast-track access to and research on psychedelic drugs (primarily ibogaine, psilocybin, and MDMA) for patients with treatment-resistant mental illness and veterans suffering from PTSD.
The order does not legalize psychedelics outright; they remain Schedule I substances under federal law.
However, it creates new regulatory pathways, dedicates $50 million in federal funding, and directs the DEA to begin rescheduling reviews upon Phase 3 trial completion, marking the most significant federal shift on psychedelic drug policy in decades.[1][2][3]
President Donald Trump signs an executive order at the White House on Saturday, April 18, 2026.
The latest science: psychedelics and mental health
Before examining the legal and regulatory landscape, it helps to understand why this executive order has gained traction. Psychedelic research has undergone a dramatic revival in the past decade, moving from the fringes of science into prestigious clinical trials at Johns Hopkins, Stanford, UCSF, Yale, and other leading institutions.[4][5]
Psilocybin (the compound in "magic mushrooms")
Psilocybin has become one of the most intensively studied psychedelics.[6][7][4]
A major umbrella review with meta-analyzed data published in late 2025 found that psilocybin demonstrated large effect sizes in treating major depressive disorder (Hedges' g ≈ 1.05), with sustained benefits in some patients lasting up to six months.
Researchers at Johns Hopkins reported in late 2024 that psilocybin's antidepressant effects may last at least one year for certain patients.
COMPASS Pathways is leading the most advanced psilocybin research program, with pivotal Phase 3 trials for treatment-resistant depression.
The FDA has granted psilocybin its Breakthrough Therapy designation — a fast-track status signaling strong early clinical evidence.
MDMA (also known as ecstasy or molly)
MDMA-assisted therapy for PTSD showed among the most impressive clinical results yet seen in psychiatry: a very large effect size in reducing PTSD symptoms (Hedges' g ≈ 1.24), often after just 2–3 treatment sessions. However, in August 2024 the FDA rejected the first application for federally approved MDMA-assisted therapy (submitted by Lykos Therapeutics) citing insufficient evidence and requiring an additional Phase 3 trial. MDMA remains in the clinical pipeline but faces additional years of development.[8][7][4]
Ibogaine
Ibogaine, derived from a shrub native to West Africa, is the central focus of Trump's executive order.[9][10][11][12]
A landmark Stanford Medicine study published in Nature Mental Health in 2025 found that ibogaine, when combined with magnesium to protect the heart, safely and effectively reduced PTSD, anxiety, and depression in veterans with traumatic brain injuries (TBI) — a population for which almost no other pharmacological treatment has worked.
Researchers noted, "No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury".
Ibogaine remains legally limited to extremely small DEA-approved research quotas; in 2024, the DEA authorized production of only 150 grams of ibogaine nationwide for research.
Its use carries serious safety risks — it can cause fatal cardiac arrhythmias and has been linked to more than 30 deaths documented in the scientific literature.
Ketamine
Ketamine is currently the only psychedelic in widespread clinical use in the United States. The FDA expanded its approval as a monotherapy for treatment-resistant depression in January 2025. Its established clinical status provides a regulatory precedent for other psychedelics.[4]
The big picture
An estimated 40–60% of people with PTSD do not respond to first-line treatments such as SSRIs, and roughly one-third of people with major depressive disorder experience treatment-resistant depression. Suicide rates increased 37% from 2000 to 2018, and over 6,000 veterans die by suicide annually — more than twice the rate of non-veteran adults. This treatment gap is the central justification driving both psychedelic research and the Trump executive order.[3][8]
The legal landscape before April 18, 2026
Schedule I classification
Before today's executive order, virtually all classical psychedelics (including psilocybin, LSD, MDMA, DMT, mescaline, and ibogaine) remained classified as Schedule I controlled substances under the Controlled Substances Act (CSA). Schedule I is the most restrictive federal drug category, reserved for substances deemed to have:[13][9]
1. A high potential for abuse
2. No currently accepted medical use in treatment
3. A lack of accepted safety for use under medical supervision[14][13]
Under Schedule I, these substances cannot be prescribed to any patient for any condition. Possession, manufacture, distribution, and dispensing are federal crimes, with the most severe criminal penalties of any controlled substance category.[15]
What research was permitted — and how hard it was
Research on Schedule I psychedelics was not prohibited, but it was extremely burdensome.[13][14]
Under the CSA, research was only permitted within federally approved scientific studies, and every researcher, institution, and facility required a separate DEA registration — a costly, time-consuming process that significantly suppressed research interest.
The administrative burden also made pharmaceutical company investment scarce, since monetizing any therapeutic use was severely limited.
The DEA did authorize annual production quotas for psychedelics, but quantities remained small for decades. In 2020, the DEA authorized only 30 grams of psilocybin for research nationwide; by 2024 that had grown to 20,000 grams, reflecting the surge in clinical trial activity.[11]
For ibogaine, only 150 grams were authorized for 2024.[11]
The FDA Breakthrough Therapy designation, granted to psilocybin and MDMA before 2026, helped somewhat by signaling priority review, but it did not remove Schedule I handling barriers or DEA registration requirements.[6]
The HALT Fentanyl Act (2025) — A partial reform
The most significant change to Schedule I research rules prior to the psychedelics executive order came from an unexpected source: the HALT Fentanyl Act, signed by President Trump on July 16, 2025.
While its primary purpose was permanently placing fentanyl-related substances into Schedule I, the law also contained meaningful research reforms:[16]
Established an expedited "notice" process to obtain DEA registration for Schedule I research
Allowed multiple related research sites to be covered under a single DEA registration
Permitted researchers working at the same institution as a DEA-registered researcher to conduct research without a separate registration
Clarified permissible manufacturing activities under a researcher registration
Created a mechanism for continuing research if a substance is classified into Schedule I during a study
Despite these reforms, the Attorney General missed the legally required deadline (January 16, 2026) to issue the interim rules implementing these changes, delaying their practical effect.[17]
Right to Try Act — Blocked as a psychedelic pathway
The Right to Try Act of 2018 (signed during Trump's first term) theoretically provided a pathway for terminally ill patients to access experimental drugs outside of clinical trials.[18][19]
Advocates pushed to use it for psychedelics — but the DEA and federal courts blocked this route.
In February 2025, the Ninth Circuit Court of Appeals ruled that the Right to Try Act did not create any exemption to the Controlled Substances Act, meaning Schedule I psychedelics remained off-limits even for terminally ill patients under Right to Try.
The DEA required standard Schedule I research registration regardless, calling psychedelic access under Right to Try "not consistent with public health and safety".
State-level exceptions
Two states (Oregon and Colorado) had legalized psilocybin therapy before the executive order, through state ballot initiatives. Oregon's program (Measure 109) established licensed psilocybin service centers; Colorado's followed a similar model. However, these state programs provided no protection from federal law and coexisted in legal tension with the CSA.[10][20][21][9]
What the executive order does
Signed on April 18, 2026, in the Oval Office — with podcast host Joe Rogan in attendance as a prominent advocate for ibogaine — the executive order titled "Accelerating Medical Treatments for Serious Mental Illness" contains five operative sections:
1. FDA Priority Review Vouchers
The order directs the FDA Commissioner to issue Commissioner's National Priority Vouchers to psychedelic drugs that have received a Breakthrough Therapy designation and meet National Priority Voucher Program criteria.[2][1][9][10][3]
These vouchers dramatically shorten FDA review timelines — from months to weeks.
FDA Commissioner Marty Makary announced that three serotonin 2a agonist psychedelics would receive these vouchers the following week, with major FDA decisions expected by summer 2026.
This marks the first time the FDA has ever provided such fast-tracking to any psychedelic substance.
2. Right to Try Pathway — Cleared for psychedelics
The order directs both the FDA and the DEA to establish a pathway for eligible patients to access investigational psychedelic drugs — including ibogaine compounds — under the Right to Try Act, including any necessary Schedule I handling authorizations for treating physicians and researchers.
This directly addresses the legal barrier that the Ninth Circuit identified in its 2025 ruling, and represents a reversal of the DEA's prior position that psychedelic access under Right to Try was inconsistent with public health.[19][3]
3. $50 million for federal-state research collaboration
The order requires the Secretary of HHS to allocate at least $50 million through the Advanced Research Projects Agency for Health (ARPA-H) to states that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses.[23][2][3]
The funding is explicitly drawn from existing appropriations and aimed at matching state-level investments, creating a federal-state collaborative research structure.
HHS Secretary RFK Jr. stated this is part of a broader strategy to tackle America's mental health crisis.
4. HHS, FDA, and VA clinical trial collaboration
The order directs HHS and the FDA to collaborate with the Department of Veterans Affairs and the private sector to increase clinical trial participation, data sharing, and real-world evidence generation for psychedelic drugs, with particular focus on Breakthrough Therapy-designated substances.
HHS, FDA, and the VA are directed to sign data-sharing memoranda to ensure clinical data flows to the FDA to facilitate timely approval.
This addresses a persistent gap: VA-conducted research has not been systematically integrated into FDA review processes.[3]
5. "Fast rescheduling" by the DEA
Section 5 is among the most consequential provisions.[1][3]
The order requires the Attorney General to initiate and complete rescheduling reviews for any Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling can proceed as quickly as possible upon FDA approval.
This is significant because previously the DEA had no obligation to initiate rescheduling reviews promptly after successful Phase 3 data — creating a potential indefinite delay between clinical evidence and legal access.
Trump characterized this as "fast rescheduling" that would go "very quickly".
What it does not do
The executive order does not:[9][3]
Legalize or decriminalize any psychedelic substance for general use
Immediately remove any substance from Schedule I
Authorize recreational or unsupervised use
Override the CSA's baseline prohibition on possession and distribution outside approved research or Right to Try frameworks
Trump himself cautioned during the signing: "I do want to emphasize: this is something that we're still studying, and we have to keep studying... We have to figure out the right way to administer it, that it's safe".[1]
Bipartisan and advocacy context
Support for psychedelic research reform has emerged as a rare bipartisan issue. [21][12][22][10][9][3]
Veterans' organizations have been among the most vocal advocates for ibogaine access, pointing to the persistent crisis of 6,000+ veteran suicides per year.
RFK Jr.'s role as HHS Secretary positioned him to advance psychedelic access as part of his broader "Make America Healthy Again" platform.
At the same time, long-time researchers expressed both excitement and caution — particularly regarding ibogaine's known cardiotoxicity, which has made U.S. trials extremely difficult to conduct.
The executive order was also framed against the backdrop of the FDA's 2024 rejection of MDMA therapy and a sense among advocates that the regulatory pathway had become an obstacle to treatments already proven effective in countries like Canada, Australia, and Portugal.[8][4]
Key implications
For patients: Terminally ill and seriously ill patients may soon gain legal access to ibogaine and other psychedelics via a Right to Try pathway — a route previously blocked by the DEA and federal courts.[19][3]
For researchers: Increased federal funding ($50M through ARPA-H), improved data-sharing between VA and FDA, and a clear rescheduling commitment upon Phase 3 success should substantially accelerate the research pipeline.[2][1]
For states: The $50 million federal-state matching program will incentivize states to create or expand psychedelic therapy programs, potentially creating an "Oregon model" nationwide.[10][2]
For the FDA and DEA: Both agencies now have explicit, time-bound presidential directives to act — reducing the regulatory inertia that has historically delayed psychedelic drug development.[3][1]
Safety concerns remain: Ibogaine's known cardiac risks mean that any expanded access program will require careful safety protocols; the NIH halted ibogaine research in the 1990s due to "cardiovascular toxicity," and the compound has been associated with more than 30 documented deaths.[12][9]
Further reading
Johns Hopkins Center for Psychedelics Research and Psilocybin Therapy
Stanford Psychedelic Science Group
University of California San Francisco Translational Psychedelic Research Program
Psilocybin and psilocin (Magic mushrooms) (Government of Canada)
Right to Try Act (FDA)
Sources
[1] How Trump is pushing psychedelics reform through the health ... https://www.statnews.com/2026/04/18/psychedelics-ptsd-mental-health-research-boost-from-trump-executive-order/
[2] Fact Sheet: President Donald J. Trump is Accelerating Medical ... https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/
[3] Accelerating Medical Treatments for Serious Mental Illness https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
[4] Psychedelics 2025: Breakthrough treatments https://grassrootsnlp.com/psychedelics-2025
[5] Johns Hopkins Center for Psychedelic and Consciousness Research https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research
[6] Psychedelic-assisted therapy: An overview for the internist https://www.ccjm.org/content/92/3/171
[7] Efficacy and Safety of Psychedelics in Mental Disorder Cases - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC12786876/
[8] The emergence of psychedelics as medicine https://www.apa.org/monitor/2024/06/psychedelics-as-medicine
[9] Trump signs order to hasten review of psychedelics | PBS News https://www.pbs.org/newshour/politics/trump-signs-order-to-speed-review-of-psychedelics
[10] Trump signs order to speed up review of psychedelic drugs for mental health treatment https://www.nbcnews.com/politics/trump-administration/excutive-order-psychedelic-drugs-ibogaine-mental-health-research-rcna340790
[11] DEA Calls For Even More THC, Psilocybin And DMT To Be ... https://www.marijuanamoment.net/dea-calls-for-even-more-thc-psilocybin-and-dmt-to-be-produced-for-research-in-2024/
[12] Psychoactive drug ibogaine effectively treats traumatic brain injury in ... https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html
[13] Are Psychedelics Legal? U.S. Laws and Policy by State 2025 https://recovered.org/hallucinogens/legal-status-of-psychedelics
[14] HALT Fentanyl Act Permanently Controls ... - Every CRS Report https://www.everycrsreport.com/reports/LSB11343.html
[15] [PDF] Federal Psychedelic Rescheduling and the Impact on State Law https://www.law.berkeley.edu/wp-content/uploads/archive/2025/11/After-Schedule-I_-Federal-Psychedelic-Rescheduling-and-the-Impact-on-State-Law.pptx.pdf
[16] HALT Fentanyl Act: Unpacking its Significant Reforms for Controlled ... https://www.ropesgray.com/en/insights/alerts/2025/07/halt-fentanyl-act-unpacking-its-significant-reforms-for-controlled-substance-research
[17] BREAKING: U.S. Attorney General Misses Legal Deadline to Issue ... https://ssdp.org/blog/attorney-general-misses-deadline-to-issue-halt-fentanyl-research-guidelines/
[18] Curious About the Right to Try? Learn What it Means for Psychedelics https://psychedelic.support/resources/curious-about-the-right-to-try-learn-what-it-means-for-psychedelics/
[19] Ninth Circuit Rejects “Right To Try” Hallucinogenic Drugs https://www.druganddevicelawblog.com/2025/02/ninth-circuit-rejects-right-to-try-hallucinogenic-drugs.html
[20] The Future of Psychedelic Regulation Is Local | Cato Institute https://www.cato.org/regulation/summer-2025/future-psychedelic-regulation-local
[21] Psychedelics & Healing Initiative Trends for 2025 https://globalwellnessinstitute.org/global-wellness-institute-blog/2025/04/02/psychedelics-healing-initiative-trends-for-2025/
[22] Trump joined by Joe Rogan as he signs order to speed up ... https://www.aljazeera.com/news/2026/4/18/trump-joined-by-joe-rogan-as-he-signs-order-to-speed-up-psychedelic-review
[23] Trump signs executive order urging more research into ibogaine ... https://www.cnn.com/2026/04/18/politics/trump-signs-executive-order-urging-more-research-into-psychedelic-ibogaine
[24] Trump signs executive order to speed review of psychedelics https://www.youtube.com/watch?v=1eNsGn7TfH0
[25] President Trump signed an executive order to fast-track the study of ... https://www.facebook.com/fox26houston/posts/president-trump-signed-an-executive-order-to-fast-track-the-study-of-using-psych/1428243782676748/
[26] Watch: Trump signs executive order easing U.S. restrictions on ... https://www.youtube.com/watch?v=b-VqZOlBVuY
[27] Trump signs executive order encouraging psychedelic drug research https://www.youtube.com/watch?v=GoHoG9cKeEc
[28] Trump announces reforms to accelerate access to psychedelic drug treatments https://www.reuters.com/world/trump-announces-reforms-accelerate-access-psychedelic-drug-treatments-2026-04-18/
[29] President Trump signed an executive order Saturday morning to ... https://www.facebook.com/CBSNews/videos/president-trump-signed-an-executive-order-saturday-morning-to-ease-restrictions-/1442592680356377/
[30] After Schedule I: Federal Psychedelic Rescheduling and the Impact ... https://www.law.berkeley.edu/research/bclt/bcltevents/after-schedule-1/
[31] The Emerging Renaissance of Psychedelic Therapy: Key Studies for Therapists and Patients https://www.webdelics.com/post/the-emerging-renaissance-of-psychedelic-therapy-key-studies-for-therapists-and-patients
[32] Federal Regulation of Psychedelic Therapies | Practical Law The ... https://www.reuters.com/practical-law-the-journal/legalindustry/federal-regulation-psychedelic-therapies-2024-08-30/
[33] Psychedelics Drug Legislative Reform ant legalization in the US - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10069558/
[34] Schedules of Controlled Substances: Rescheduling of Marijuana https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
[35] Increasing Medical Marijuana and Cannabidiol Research https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/
[36] The Most Important Schedule I Drug Regulatory Shifts Of 2024 https://www.law360.com/articles/2287629/the-most-important-schedule-i-drug-regulatory-shifts-of-2024
[37] Federal Bill Would Give Some Patients "Right to Try" Psychedelics https://filtermag.org/patient-right-to-try-psychedelics/
[38] Psychedelic Research: Clinical Trials & Timelines | Report https://prohibitionpartners.com/2025/12/18/psychedelic-research-clinical-trials-timelines-and-key-research-groups-psych-the-psychedelics-as-medicine-report-3rd-edition/
[39] S. 331, HALT Fentanyl Act | Congressional Budget Office https://www.cbo.gov/publication/61243
[40] Include Certain Psychedelics in Right to Try, Bill Proposes https://leadingage.org/include-certain-psychedelics-in-right-to-try-bill-proposes/
[41] Parents, Police, and Advocates Condemn Senate Passage of HALT ... https://drugpolicy.org/news/parents-police-and-advocates-condemn-senate-passage-of-halt-fentanyl-act-demand-lifesaving-health-solutions-to-fentanyl-and-overdose/
[42] Ninth Circuit Punts on "Right to Try" Psilocybin Litigation - Harris Sliwoski LLP https://harris-sliwoski.com/psychlawblog/ninth-circuit-punts-on-right-to-try-psilocybin-litigation/
[43] A review of psychedelics trials completed in depression, informed by ... https://www.sciencedirect.com/science/article/pii/S2772408525001085
Image source: Pixabay